Ironwood Pharmaceuticals to Host Second Quarter 2013 Investor Update Call

  Ironwood Pharmaceuticals to Host Second Quarter 2013 Investor Update Call

Business Wire

CAMBRIDGE, Mass. -- July 9, 2013

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will host its
second quarter 2013 investor update conference call and webcast at 8:30 a.m.
Eastern Time on Tuesday, July 23, 2013. Individuals interested in
participating in the call should dial (877) 643-7155  (U.S. and Canada) or
(914) 495-8552 (international) using conference ID number 14769645. To access
the webcast, please visit the Investors section of Ironwood’s website at
www.ironwoodpharma.com at least 15 minutes prior to the start of the call to
ensure adequate time for any software downloads that may be required.

The call will be available for replay via telephone starting July 23, 2013 at
approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time
on July 30, 2013. To listen to the replay, dial (855) 859-2056 (U.S. and
Canada) or (404) 537-3406 (international) using conference ID number 14769645.
The archived webcast will be available on Ironwood’s website for 14 days
beginning approximately one hour after the call has completed.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (NASDAQ: IRWD) is committed to the art and science of
making medicines, from discovery through commercialization. We’re focused on
three goals: transforming knowledge into medicines that make a difference for
patients, creating value that will inspire the continued support of our fellow
shareholders, and building a team that passionately pursues excellence. Our
first product, linaclotide, is approved in the United States and Europe. Our
pipeline priorities include exploring further opportunities for linaclotide,
leveraging our deep expertise in functional gastrointestinal disorders, and
advancing programs in other areas such as allergic conditions, cardiovascular
disease, central nervous system disorders and other conditions defined by
patient symptoms.Ironwood was founded in 1998 and is headquartered in
Cambridge, Mass. Connect with us at www.ironwoodpharma.com or on Twitter at
www.twitter.com/ironwoodpharma to learn more about Ironwood. Information that
may be important to investors will be routinely posted in both these
locations.

Contact:

Ironwood Pharmaceuticals, Inc.
Media Relations
Lisa Buffington, 617-374-5103
Vice President, Corporate Communications
lbuffington@ironwoodpharma.com
or
Investor Relations
Meredith Kaya, 617-374-5082
Associate Director, Investor Relations
mkaya@ironwoodpharma.com
 
Press spacebar to pause and continue. Press esc to stop.